Retinoid

EQS-News: CHEPLAPHARM acquires Roaccutane® from Roche

Retrieved on: 
Tuesday, January 30, 2024
Dermatology, Retinoid, Acne, Isotretinoin, Medicine, Intellectual property, Cheplapharm Arzneimittel, Fine chemical

The CHEPLAPHARM Group acquires the global rights to Roaccutane® from Roche, thereby strengthening its dermatological portfolio.

Key Points: 
  • The CHEPLAPHARM Group acquires the global rights to Roaccutane® from Roche, thereby strengthening its dermatological portfolio.
  • The medicine, which is based on the active ingredient isotretinoin, is used to treat severe acne.
  • CHEPLAPHARM, a leading purchaser of originator products from research-based pharmaceutical companies, has acquired the global rights to Roaccutane® from Roche, which include around 50 countries.
  • CHEPLAPHARM is already active in the therapeutic area of dermatology and owns medicines for the topical treatment of mild forms of acne and antibiotic-based products for mild to moderate forms of acne.

OLEHENRIKSEN LAUNCHES FIRST RETINOL: INTRODUCING DOUBLE REWIND PRO-GRADE 0.3% RETINOL SERUM

Retrieved on: 
Tuesday, January 2, 2024
Serum, Elasticity, John Foster Dulles, Retinoid, Skin, Cosmetics

NEW YORK, Jan. 2, 2024 /PRNewswire/ -- Renew and replenish skin with Double Rewind Pro-Grade 0.3% Retinol Serum, OLEHENRIKSEN's new silky dual-action retinol here to pave the way to an improved retinol experience. Clinically proven to visibly reduce the appearance of wrinkles and retexturize skin in just two weeks, this powerful yet balanced formula is the key to restoring youthful skin. It's time to hit rewind on your wrinkles with each joyful application of OLEHENRIKSEN's new Double Rewind Pro-Grade 0.3% Retinol Serum. 

Key Points: 
  • NEW YORK, Jan. 2, 2024 /PRNewswire/ -- Renew and replenish skin with Double Rewind Pro-Grade 0.3% Retinol Serum , OLEHENRIKSEN's new silky dual-action retinol here to pave the way to an improved retinol experience.
  • It's time to hit rewind on your wrinkles with each joyful application of OLEHENRIKSEN's new Double Rewind Pro-Grade 0.3% Retinol Serum.
  • OLEHENRIKSEN Double Rewind Pro-Grade 0.3% Retinol Serum takes retinol to the next level, combining a results-driven, anti-aging serum with soothing Scandinavian ingredients to nourish, hydrate and strengthen skin while visibly improving the appearance of fine lines and wrinkles.
  • Providing a sensorial application experience with a plush, cloud-like texture, Double Rewind Pro-Grade 0.3% Retinol Serum absorbs effortlessly into the skin sans stickiness.

China Medical System: NDA for Additional RA Indication of Methotrexate Injection Accepted in China

Retrieved on: 
Monday, December 4, 2023
Marketing, Light, PUVA, MTX, European, Methotrexate, Blue, NDA, Rheumatoid arthritis, Tablet, New Drug Application, NMPA, Study, Gemeinschaft and Gesellschaft, Retinoid, National Medical Products Administration, Patient, Safety, Psoriasis, Injection, Communication, Pharmaceutical industry

The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis indication of Methotrexate Injection.

Key Points: 
  • The New Drug Application for an additional rheumatoid arthritis (RA) indication of Methotrexate Injection has been accepted by NMPA, which is a new milestone following the China approval for psoriasis indication of Methotrexate Injection.
  • The Product is expected to become the first methotrexate (MTX) prefilled injection to treat RA by subcutaneous administration in China.
  • China Medical System Holdings Limited ( “CMS” or the “Group”) announced that on 4 December 2023, the New Drug Application (NDA) for an additional indication of its innovative product, Methotrexate Injection (the “Product”), has been accepted by the National Medical Products Administration of China (NMPA).
  • The Product is a small-volume methotrexate injection with various strengths, which is intended to be used to treat active rheumatoid arthritis (RA) in adult patients.

SciTech Development Announces The Formation of a Distinguished Medical Advisory Board With Top Oncology Specialists

Retrieved on: 
Thursday, October 26, 2023
FAAD, Laboratory, FDA, Columbia University Irving Medical Center, FARMS, SciTech, University of Washington School of Medicine, Duke University, Therapy, SDP, MD, Publication, Retinoid, Duke University School of Medicine, Bone marrow, Fenretinide, Division, Clinical trial, Internal medicine, MAB, Emory University, Malignancy, Bexarotene, University, Immediate, Safety, Cancer, International Society, Patient, Toxicity, Fred Hutchinson Cancer Research Center, Lymphoma, Vaccine, Pharmaceutical industry, Research, Dermatology, Medicine

GROSSE POINTE FARMS, Mich., Oct. 26, 2023 /PRNewswire/ -- SciTech Development, LLC, today announced the formation of a distinguished and independent medical advisory board (MAB) comprised of key opinion leaders and world-renowned experts in T-Cell Lymphomas and hematological malignancies.

Key Points: 
  • GROSSE POINTE FARMS, Mich., Oct. 26, 2023 /PRNewswire/ -- SciTech Development, LLC, today announced the formation of a distinguished and independent medical advisory board (MAB) comprised of key opinion leaders and world-renowned experts in T-Cell Lymphomas and hematological malignancies.
  • The board will provide strategic and clinical advice for SciTech's outreach and education initiatives within the oncology community.
  • The three medical advisors appointed to the board are Madeleine Duvic, M.D., Larisa Geskin, M.D., and Ajay Gopal, M.D.
  • Madeleine Duvic, MD – "The development of ST-100 is exciting because this new drug holds the promise of improved bioavailability, leading to increased efficacy with low toxicity."

Retinol: what is it and why is it considered a modern anti-ageing skincare essential?

Retrieved on: 
Friday, August 4, 2023
Tretinoin, Retinoid, All-trans-retinyl ester 13-cis isomerohydrolase, Skin, US Foods, Instability, Oxygen, Elastin, Light, Acne, Vitamin A, Cosmetics, Research, Vegetable, Sale, Psoriasis, Sunlight, Retinal, Immune system, Growth, Collagen, ECM, Bacteria, Hand, Environment, Nanotechnology, Food, Scleroderma, Wound healing, Dietary supplement, Sulfur, EU, Atlantic Ocean

Of all the wonder ingredients promoted by skincare enthusiasts and manufacturers, retinol is among the most popular. It’s a potent ingredient that can help with a wide variety of complaints, from wrinkles to acne. But how does it work and should you just go out and buy the first retinol product you see?What is retinol?Vitamin A is an essential micronutrient that plays a vital role in supporting various physiological functions in most mammal species.

Key Points: 


Of all the wonder ingredients promoted by skincare enthusiasts and manufacturers, retinol is among the most popular. It’s a potent ingredient that can help with a wide variety of complaints, from wrinkles to acne. But how does it work and should you just go out and buy the first retinol product you see?

What is retinol?

    • Vitamin A is an essential micronutrient that plays a vital role in supporting various physiological functions in most mammal species.
    • It promotes normal vision, bolsters the immune system, facilitates reproduction and fosters optimal growth and development.
    • It can help maintain skin health and, because it stimulates collagen and elastin biosynthesis, it can enhance the skin’s regenerative mechanisms.

Retinol

    • When retinol is applied topically, it is converted into retinoic acid by the skin, the biologically active form of vitamin A.
    • This is why you often see retinol skincare products packaged in opaque bottles, which protect them from the sunlight.
    • Some manufacturers recommend keeping retinol products in the fridge, and most skincare retinol products have a limited shelf-life.

Retinyl

    • The most common forms are retinyl acetate and retinyl palmitate.
    • Retinyl needs to be converted into retinol and then into retinoic acid by the skin in order to be functional.

Retinaldehyde

    • Retinaldehyde, also known as retinal, is more potent than retinol but less potent than retinoic acid.
    • Due to its proximity to retinoic acid, retinaldehyde is considered more efficient in producing skin benefits compared with retinol.

Which to choose

    • Generally, over-the-counter cosmetic products may contain retinol concentrations ranging from 0.1% to 1%.
    • These concentrations are lower than prescription-strength retinoids, which can contain higher amounts of retinol or more potent derivatives such as tretinoin.
    • This is why you might see stronger retinol products on sale in markets such as the US, compared with Europe or countries that trade heavily with Europe.
    • The retinyl esters are the most stable but have not shown significant differences when used on the skin, compared with a placebo.

Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan

Retrieved on: 
Thursday, June 29, 2023
Research, FDA, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Oncology, Hepatology, Feedback, European Medicines Agency, New Drug Application, Acitretin, NDA, Psoriasis, Methotrexate, History, Marketing, EMA, Patient, CANF, TASE, Adolescence, Steroid, MAA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Retinoid, Food, Safety, Disease, Pharmaceutical industry

The FDA had a positive view of the non-clinical studies conducted by the Company and the accumulated safety data that the Company submitted to the agency as part of the registration plan.

Key Points: 
  • The FDA had a positive view of the non-clinical studies conducted by the Company and the accumulated safety data that the Company submitted to the agency as part of the registration plan.
  • The FDA provided advice on the randomized, double-blind, placebo-controlled Phase 3 clinical trial protocol with Piclidenoson that is aimed at demonstrating clinical safety and efficacy for the treatment of patients with moderate to severe plaque psoriasis.
  • Psoriasis affects millions of people worldwide, including a significant number of adolescents who endure the physical and emotional burden of this challenging disease.
  • The Company believes that Piclidenoson represents a promising oral option for this underserved population.

The Worldwide Psoriasis Therapeutics Industry is Estimated to Reach $55.8 Billion by 2031 at a 9.3% CAGR - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 25, 2023
Retail, Pharmaceutical, Health, Other Retail, Wuhan Institute of Biological Products, Benchmarking, Administration, Skin, Therapy, Rash, Common, Maharashtra University of Health Sciences, Plaque, Patient, Route of administration, Porter's five forces analysis, Psoriasis, Family, Growth, Scalp, Prevalence, Pharmaceutical industry, Cosmetics, Marketing, Retinoid

According to this report the psoriasis therapeutics market size was valued at $22.9 billion in 2021, and is estimated to reach $55.8 billion by 2031, growing at a CAGR of 9.3% from 2022 to 2031.

Key Points: 
  • According to this report the psoriasis therapeutics market size was valued at $22.9 billion in 2021, and is estimated to reach $55.8 billion by 2031, growing at a CAGR of 9.3% from 2022 to 2031.
  • Psoriasis is a skin disorder that causes skin cells to multiply up to 10 times faster than normal.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the psoriasis therapeutics market analysis from 2021 to 2031 to identify the prevailing psoriasis therapeutics market opportunities.
  • The report includes the analysis of the regional as well as global psoriasis therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Global Psoriasis Therapeutics Market Report to 2031 - Featuring Abbvie, Amgen, Bausch Health, LEO Pharma and Novan Among Others

Retrieved on: 
Wednesday, January 25, 2023
Therapy, Scalp, Common, Psoriasis, Plaque, Skin, Rash, Route of administration, Maharashtra University of Health Sciences, Porter's five forces analysis, Growth, Benchmarking, Prevalence, Patient, Family, Administration, Wuhan Institute of Biological Products, Pharmaceutical industry, Cosmetics, Marketing, Retinoid

According to this report the psoriasis therapeutics market size was valued at $22.9 billion in 2021, and is estimated to reach $55.8 billion by 2031, growing at a CAGR of 9.3% from 2022 to 2031.

Key Points: 
  • According to this report the psoriasis therapeutics market size was valued at $22.9 billion in 2021, and is estimated to reach $55.8 billion by 2031, growing at a CAGR of 9.3% from 2022 to 2031.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the psoriasis therapeutics market analysis from 2021 to 2031 to identify the prevailing psoriasis therapeutics market opportunities.
  • In-depth analysis of the psoriasis therapeutics market segmentation assists to determine the prevailing market opportunities.
  • The report includes the analysis of the regional as well as global psoriasis therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Global Dermatology Medical Lasers Market 2022 to 2031 - Featuring Cynosure, Miracle Laser, Syneron and Shenzhen GSD Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022
Surgery, Health, Medical Devices, Dermatology, Woman, Rosacea, COVID-19, Skin, Plastic, Hair removal, Isotretinoin, Conditional sentence, Cancer, American Society of Plastic Surgeons, Growth, FDA, GSD, Acne, Cynosure, Society, Picolo, Hospital, Laser, Pharmacotherapy, Retinoid, Petroleum jelly

Major players in the dermatology medical lasers market are Cynosure, Peninsula, Miracle Laser, Syneron, Shenzhen GSD, Sincoheren, Fotona, Alma Lasers Ltd, and Cutera.

Key Points: 
  • Major players in the dermatology medical lasers market are Cynosure, Peninsula, Miracle Laser, Syneron, Shenzhen GSD, Sincoheren, Fotona, Alma Lasers Ltd, and Cutera.
  • The dermatology medical lasers market consists of sales of dermatology medical lasers and related services by companies that manufacture them.
  • The main devices of dermatology medical lasers are surgical lasers and vascular lasers.
  • Therefore, the use of picosecond lasers in dermatological processes is expected to be the new trend in the dermatology medical lasers market.

T-cell Lymphoma Global Market Report 2022: Advancements in Combination Therapies for Peripheral T-Cell Lymphoma Present Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 15, 2022
General Health, Hospitals, Health, Pharmaceutical, Oncology, T-cell lymphoma, Acquisition, Customer support, Mergers and acquisitions, Growth, Business Growth Fund, End user, Treatment, News, Use, Research report, COVID-19, Strategic management, Weakness, Hospital, Economic development, Collaborative partnership, Investment, Market share analysis, Value, Retail, Retinoid

The "T-cell lymphoma Market Research Report by Treatment, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "T-cell lymphoma Market Research Report by Treatment, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
  • The Global T-cell lymphoma Market is projected to grow with a significant CAGR in the forecast period.
  • Further, the patterns associated with domestic production, import and export, and consumption have helped market participants to analyze and capitalize on potential opportunities.
  • Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the Global T-cell lymphoma Market.